Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.34 |
| ▸ | SCN4A | P35499 | 4/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6355236 | 0.88 | RAPGEF4 (0.39) | TSHRRAPGEF4SCN4ACYP3A4MAPT | |
| SCHEMBL25247894 | 0.84 | SCN4A (0.30) | RAPGEF4SCN4A | |
| SCHEMBL21803257 | 0.84 | SCN4A (0.30) | SCN4A | |
| SCHEMBL585059 | 0.78 | HRH3 (0.40) | TSHRRAPGEF4MAPT | |
| SCHEMBL893003 | 0.78 | ALDH1A1 (0.41) | TSHRCYP3A4 | |
| SCHEMBL21749452 | 0.76 | HTR1D (0.41) | — | |
| SCHEMBL21472699 | 0.76 | RAPGEF4 (0.40) | TSHRRAPGEF4SCN4ACES1CYP3A4 | |
| SCHEMBL14524295 | 0.76 | TSHR (0.37) | TSHRRAPGEF4SCN4ACES1CYP3A4 | |
| SCHEMBL16670956 | 0.76 | TRPA1 (0.33) | TSHR | |
| SCHEMBL17648045 | 0.76 | HRH3 (0.39) | TSHRRAPGEF4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774719-B1 | METHOD FOR THE PREPARATION OF 2.6-DIALKYLPHENYL ACETIC ACIDS | BAYER AG (DE) | 2025-07-23 | — | — | EP | disclosed |
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | FIBROGEN, INC. | 2024-01-04 | — | — | US | disclosed |
| EP-4204400-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | Fibrogen, Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| US-11691938-B2 | Process for preparing 2,6-dialkylphenylacetic acids | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-04 | — | — | US | disclosed |
| US-11691938-B2 | Process for preparing 2,6-dialkylphenylacetic acids | BAYER AKTIENGESELLSCHAFT (DE) | 2023-07-04 | — | — | US | disclosed |
| CN-116348450-A | Compounds, compositions and methods for histone lysine demethylase inhibition | 菲布罗根有限公司 | 2023-06-27 | — | — | CN | disclosed |
| WO-2022047230-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | FIBROGEN, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| US-20210403406-A1 | PROCESS FOR PREPARING 2,6-DIALKYLPHENYLACETIC ACIDS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-12-30 | — | — | US | disclosed |
| CN-112004795-A | Process for preparing 2, 6-dialkylphenylacetic acid | 拜耳公司 | 2020-11-27 | — | — | CN | disclosed |
| WO-2019197232-A1 | PROCESS FOR PRODUCING 2,6-DIALKYLPHENYL ACETIC ACIDS | BAYER AKTIENGESELLSCHAFT (DE) | 2019-10-17 | — | — | WO | disclosed |
| US-20030220364-A1 | New compounds | AMIN KOSRAT (SE) | 2003-11-27 | — | — | US | disclosed |
| US-6579884-B1 | Compounds | ASTRAZENECA AB (SE) | 2003-06-17 | — | — | US | disclosed |
| CN-1100056-C | Compound for inhibition of gastric acid secretion | ASTRA AB (SE) | 2003-01-29 | — | — | CN | disclosed |
| EP-0971920-B1 | COMPOUNDS FOR INHIBITION OF GASTRIC ACID SECRETION | ASTRAZENECA AB (SE) | 2002-06-05 | — | — | EP | disclosed |
| US-6265415-B1 | ANTIULCER AGENT | ASTRAZENECA AB (SE) | 2001-07-24 | — | — | US | disclosed |
| EP-1105391-A2 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2001-06-13 | — | — | EP | disclosed |
| CN-1248257-A | Compound for inhibition of gastric acid secretion | ASTRA AB (SE) | 2000-03-22 | — | — | CN | disclosed |
| WO-2000011000-A2 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2000-03-02 | — | — | WO | disclosed |
| EP-0971920-A1 | COMPOUNDS FOR INHIBITION OF GASTRIC ACID SECRETION | Astra Aktiebolag (SE) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998037080-A1 | COMPOUNDS FOR INHIBITION OF GASTRIC ACID SECRETION | ASTRA AKTIEBOLAG (SE) | 1998-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220364-A1 | New compounds | SLC10A2, GIPR, FABP2 | TSHR 2682/4885RAPGEF4 1067/4885SCN4A 2992/4885 |
| US-20210403406-A1 | PROCESS FOR PREPARING 2,6-DIALKYLPHENYLACETIC ACIDS | ADH1C, ADH1A, ADH5 | TSHR 4521/4885RAPGEF4 1649/4885SCN4A 724/4885 |
| US-11691938-B2 | Process for preparing 2,6-dialkylphenylacetic acids | ADH1C, ADH1A, ADH5 | TSHR 4521/4885RAPGEF4 1649/4885SCN4A 724/4885 |
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | KDM5C, KDM5B, KDM5A | TSHR 4662/4885RAPGEF4 2692/4885SCN4A 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.